SCHEMBL22130672

SCHEMBL22130672

COc1ccc(C2=CC(=O)C(=O)c3c(-c4ccccc4)cn(S(C)(=O)=O)c32)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELAVL1 Q15717 5/20 0.80
PTPN1 P18031 4/20 0.52
BACE1 P56817 3/20 0.48
PTGS2 P35354 1/20 0.43
PTPRC P08575 1/20 0.40
PTPRF P10586 1/20 0.40
CDC25B P30305 1/20 0.40
HDAC4 P56524 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
PDE4B Q07343 1/20 0.39
GFER P55789 1/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
PKM P14618 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
MCL1 Q07820 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22130669 0.91 ELAVL1 (0.64) ELAVL1PTPN1BACE1PTGS2PTPRC
SCHEMBL22130724 0.89 ELAVL1 (1.00) ELAVL1PTPN1BACE1PTGS2MAPT
SCHEMBL21222570 0.77 ELAVL1 (0.80) ELAVL1PTPN1BACE1PTPRCPTPRF
SCHEMBL22130709 0.76 ELAVL1 (0.54) ELAVL1PTPN1BACE1PTGS2PTPRC
SCHEMBL22130712 0.75 ELAVL1 (0.55) ELAVL1PTPN1PTGS2
SCHEMBL22130710 0.75 ELAVL1 (0.55) ELAVL1PTPN1PTGS2PTPRCPTPRF
SCHEMBL22130711 0.74 ELAVL1 (0.54) ELAVL1PTPN1PTGS2
SCHEMBL22130718 0.74 ELAVL1 (0.54) ELAVL1PTGS2KDM4EMAPK1KMT2A
SCHEMBL19737482 0.69 ELAVL1 (0.77) ELAVL1PTGS2HDAC4HDAC2HDAC8
SCHEMBL21222504 0.68 HTR6 (0.50) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy AZI2, TPMT, TYMS ELAVL1 2765/4885PTPN1 1930/4885BACE1 3309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.